{
  "type": "article",
  "title": "Biotech Firm Defends Working With Trump as Conservationists Question De-Extinction Priorities",
  "summary": "Colossal Biosciences CEO Ben Lamm defended partnering with the Trump administration on an endangered species biobank, acknowledged missing the 2028 woolly mammoth target, and ruled out resurrecting prehistoric sharks like megalodon.",
  "content": "Colossal Biosciences, the genetics company known for its ambitions to bring back extinct creatures, has secured backing from the Trump administration for an initiative aimed at preserving genetic material from endangered wildlife. Addressing an audience at a public technology forum, Chief Executive Officer Ben Lamm explained the strategic rationale behind engaging with the White House, asserting that facing dire environmental outlooks means one cannot simply bury their head in the sand for four years.\n\nConservation Concerns and Biobanking Strategy\nThe collaboration comes despite an administration that has historically shown little enthusiasm for traditional land and wildlife preservation policies. Conservation specialists have raised sharp concerns about Colossal partnering with the Trump administration earlier this year on the biobanking project. Critics contend that elevating future de-extinction programs diverts vital focus from shielding existing species from extinction right now. The concern is that if policymakers believe science can resurrect lost animals later, urgency around habitat preservation and anti-poaching measures today might decline. Lamm argued that collecting and banking genetic samples has become indispensable as climate degradation and loss of natural habitats accelerate pressure on global biodiversity.\n\nSurging Valuation, Spinoffs, and Working Dogs\nColossal secured $230 million in its Series C funding round last year, an influx of capital that established its market valuation at $10.2 billion. The biotechnology venture is now in talks to assemble another capital round, seeking a valuation ranging between $20 billion and $30 billion. Beyond its flagship prehistoric targets, the startup has launched several spinoff enterprises. One spinoff utilizes engineered microbes to break down plastic waste. Colossal also holds an equity stake in Warhound, a specialized venture developed by Lamm alongside Anduril Chief Executive Officer Palmer Luckey. Warhound aims to engineer genetically enhanced dogs tailored for law enforcement, military operations, and emergency response teams. Lamm noted that this initiative applies biobanking principles to cut reliance on commercial puppy mills producing working canines in Europe.\n\nMammoth Timeline Slips and Scientific Scrutiny\nPublic attention has surrounded Colossal for claims involving the creation of woolly mice and efforts to reconstruct dire wolves as stepping stones toward resurrecting the woolly mammoth. Independent scientists and critics, however, have questioned whether the venture emphasizes publicity over core scientific substance. When the company unveiled its dire wolves, scientific observers pointed out that their genomic architecture remains remarkably close to modern gray wolves. David Jachowski, a professor at Clemson University, noted that defining distinct species inherently involves an element of subjectivity. Lamm acknowledged that Colossal will miss its initial 2028 target for producing a woolly mammoth, even though researchers have completed 130 specific modifications to mammoth genes. He added that he is unbothered whether critics label the animals gene-edited gray wolves or refer to forthcoming mammoths as hairy elephants.\n\nFuture Announcements and Leaving Ocean Predators Alone\nDespite persistent skepticism regarding promotional hype, Lamm maintained that Colossal has actually understated its technical progress in genome editing, promising further major milestones that will surprise the public. He drew a firm boundary, however, at prehistoric marine apex predators. Despite heavy public interest urging the company to consider reviving the giant prehistoric shark megalodon, Lamm made it clear that such projects are entirely off the table, humorously observing that the ocean is already terrifying enough without them.\n\nWhat this means for you\nThe expansion of high-profile biobanking highlights a shifting balance between practical field conservation and high-capital genomic engineering.\n\n• Impact on Wildlife Conservation: Banking endangered species DNA creates a genetic safeguard against permanent loss, but critics caution it risks weakening funding for immediate habitat preservation. Policy officials might mistakenly view de-extinction as a substitute for enforcing strict land protections.\n• Biotechnology and Career Growth: Colossal's projected valuation of up to $30 billion signals sustained capital investment in synthetic biology. This expansion opens up research infrastructure and specialized jobs for molecular biologists, computational geneticists, and bioengineers.\n• Law Enforcement and Defense: Ventures like Warhound introducing genetically optimized working dogs will alter capability standards for tactical security units. It will also force regulatory authorities to establish new legal guidelines surrounding commercially bred, gene-edited service animals.\n• Practical Applications for Everyday Life: Environmental spinoffs targeting plastic degradation via specialized microbes could yield useful consumer waste breakthroughs. Conversely, members of the public expecting to see living woolly mammoths by 2028 will face delayed scientific timelines.\n\nWhy this happened\nThe partnership between Colossal Biosciences and the Trump administration stems from urgent biodiversity challenges alongside strategic business positioning.\n\n• Accelerating Biodiversity Loss: Rapid destruction of natural habitats and climate stresses are driving endangered species toward extinction at an alarming pace. Lamm defended working with federal authorities because archiving genetic material cannot pause for political election cycles.\n• Pushback from Environmental Scientists: Conservationists raised alarms because speculative promises of reviving extinct animals could incentivize governments to relax ongoing land and wildlife protections. This philosophical clash triggered immediate public scrutiny once federal cooperation was initiated.\n• Commercial Scale and Capital Ambitions: Pursuing an upgraded valuation of up to $30 billion requires Colossal to prove tangible utility through government-aligned programs and practical spinoffs. Launching environmental and tactical canine initiatives demonstrates real-world commercial viability beyond long-term academic targets.\n• Genomic Engineering Hurdles: While researchers executed 130 genomic modifications, reconstructing the complex biology of an ancient creature demands far more laboratory iterations than anticipated. These scientific realities forced the company to concede its 2028 target date while shelving unfeasible concepts like the megalodon.\n\nQuestions & Answers\n\n1. What project is Colossal Biosciences pursuing with the Trump administration?\nColossal is partnering with the administration to establish a biobank containing preserved DNA samples from endangered wildlife species.\n\n2. Why did Ben Lamm say you cannot put your head in the sand for four years?\nLamm argued that severe biodiversity loss requires active engagement with government authorities rather than ignoring conservation initiatives during an administration's tenure.\n\n3. Will Colossal meet its original deadline for reviving the woolly mammoth?\nNo, the company acknowledged that it will miss its initial 2028 target date for producing a woolly mammoth.\n\n4. What is Colossal's current valuation and its target for the new fundraising round?\nThe company was valued at $10.2 billion after its $230 million Series C, and it is now seeking a new valuation between $20 billion and $30 billion.\n\n5. What is the focus of the Warhound startup created by Ben Lamm and Palmer Luckey?\nWarhound focuses on developing genetically enhanced working dogs for military, police, and emergency responders while curbing reliance on European commercial puppy mills.\n\n6. Is Colossal planning to resurrect the prehistoric shark megalodon?\nNo, Lamm firmly ruled out working on the megalodon, stating that the company will not pursue prehistoric marine predators.",
  "url": "https://trendkia.com/en/science/trump-prashasana-ke-satha-kama-karane-para-colossal-ke-ben-lamm-bole-chara-sala-taka-reta-men-sira-chhipakara-nahin-baitha-sakate-56677",
  "category": "Science",
  "publishedAt": "2026-11-04",
  "tags": [
    "Colossal Biosciences",
    "Ben Lamm",
    "Donald Trump",
    "Woolly Mammoth",
    "Gene Editing",
    "Biobanking",
    "Dire Wolf"
  ],
  "language": "en",
  "site": "TrendKia",
  "whatItMeansForYou": "The expansion of high-profile biobanking highlights a shifting balance between practical field conservation and high-capital genomic engineering.\n\n• Impact on Wildlife Conservation: Banking endangered species DNA creates a genetic safeguard against permanent loss, but critics caution it risks weakening funding for immediate habitat preservation. Policy officials might mistakenly view de-extinction as a substitute for enforcing strict land protections.\n• Biotechnology and Career Growth: Colossal's projected valuation of up to $30 billion signals sustained capital investment in synthetic biology. This expansion opens up research infrastructure and specialized jobs for molecular biologists, computational geneticists, and bioengineers.\n• Law Enforcement and Defense: Ventures like Warhound introducing genetically optimized working dogs will alter capability standards for tactical security units. It will also force regulatory authorities to establish new legal guidelines surrounding commercially bred, gene-edited service animals.\n• Practical Applications for Everyday Life: Environmental spinoffs targeting plastic degradation via specialized microbes could yield useful consumer waste breakthroughs. Conversely, members of the public expecting to see living woolly mammoths by 2028 will face delayed scientific timelines.",
  "whyItHappened": "The partnership between Colossal Biosciences and the Trump administration stems from urgent biodiversity challenges alongside strategic business positioning.\n\n• Accelerating Biodiversity Loss: Rapid destruction of natural habitats and climate stresses are driving endangered species toward extinction at an alarming pace. Lamm defended working with federal authorities because archiving genetic material cannot pause for political election cycles.\n• Pushback from Environmental Scientists: Conservationists raised alarms because speculative promises of reviving extinct animals could incentivize governments to relax ongoing land and wildlife protections. This philosophical clash triggered immediate public scrutiny once federal cooperation was initiated.\n• Commercial Scale and Capital Ambitions: Pursuing an upgraded valuation of up to $30 billion requires Colossal to prove tangible utility through government-aligned programs and practical spinoffs. Launching environmental and tactical canine initiatives demonstrates real-world commercial viability beyond long-term academic targets.\n• Genomic Engineering Hurdles: While researchers executed 130 genomic modifications, reconstructing the complex biology of an ancient creature demands far more laboratory iterations than anticipated. These scientific realities forced the company to concede its 2028 target date while shelving unfeasible concepts like the megalodon.",
  "questionsAndAnswers": [
    {
      "question": "What project is Colossal Biosciences pursuing with the Trump administration?",
      "answer": "Colossal is partnering with the administration to establish a biobank containing preserved DNA samples from endangered wildlife species."
    },
    {
      "question": "Why did Ben Lamm say you cannot put your head in the sand for four years?",
      "answer": "Lamm argued that severe biodiversity loss requires active engagement with government authorities rather than ignoring conservation initiatives during an administration's tenure."
    },
    {
      "question": "Will Colossal meet its original deadline for reviving the woolly mammoth?",
      "answer": "No, the company acknowledged that it will miss its initial 2028 target date for producing a woolly mammoth."
    },
    {
      "question": "What is Colossal's current valuation and its target for the new fundraising round?",
      "answer": "The company was valued at $10.2 billion after its $230 million Series C, and it is now seeking a new valuation between $20 billion and $30 billion."
    },
    {
      "question": "What is the focus of the Warhound startup created by Ben Lamm and Palmer Luckey?",
      "answer": "Warhound focuses on developing genetically enhanced working dogs for military, police, and emergency responders while curbing reliance on European commercial puppy mills."
    },
    {
      "question": "Is Colossal planning to resurrect the prehistoric shark megalodon?",
      "answer": "No, Lamm firmly ruled out working on the megalodon, stating that the company will not pursue prehistoric marine predators."
    }
  ]
}